Esophageal Cancer

The addition of tislelizumab to first-line chemotherapy extended OS among patients with advanced esophageal cancer, according to study results presented at European Society for Medical Oncology World Congress on Gastrointestinal Cancer.

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma.

Between 2012 and 2019, esophageal cancer rates nearly doubled and prevalence of Barrett’s esophagus increased by 50% among adults aged 45 to 64 years, according to researchers.

Paclitaxel plus fluorouracil did not demonstrate OS superiority over paclitaxel plus cisplatin or paclitaxel plus carboplatin in definitive chemoradiation for locally advanced esophageal squamous cell carcinoma.

The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from the agent’s manufacturer.

Esophageal cancer is one of the deadliest forms of cancer with an estimated 19,260 diagnoses and 15,530 deaths in the United States last year, the American Association for Cancer Research reported.

Patients with esophageal cancer who engaged in prehabilitation exercise demonstrated improved responses to neoadjuvant chemotherapy than those who did not, according to a study published in British Journal of Sports Medicine.

The addition of docetaxel to cisplatin and 5-FU chemotherapy significantly extended OS as neoadjuvant therapy for local advanced esophageal squamous cell cancer, according to results of a randomized phase 3 trial.

The FDA granted orphan drug designation to toripalimab for the treatment of esophageal cancer.

The FDA granted orphan drug designation to DF1001 for treatment of esophageal cancer.